Pioneering in Genetic Medicine and Infectious Disease Vaccines for Tomorrow using Proprietary Breakthrough Technology
Scientists and Physicians at Luminous Therapeutics are making significant strides in the treatment of infectious diseases and rare diseases, both at the forefront of medical research and on the front lines of patient care. Self-amplifying RNA vaccines are highly versatile. saRNA is beneficial compared to non-amplifying RNA as it has the advantages of rapid development, plug-and-play modular design, cell-free synthesis, but with the added advantage of lower dose level due to self-replicating. Our RNA therapeutic platforms have immense potential; however, there are many hurdles that need to be overcome when they are developed clinically to make them effective potential treatment options, especially for rare diseases.
Getting ahead of infectious diseases with advanced “Targeted Delivery Mechanisms” to deliver antigens to upper and lower respiratory tract
Our proprietary Lipid nanoparticle libraries and platforms are primed for SELECTIVE ORGAN TARGETING delivery of RNA cargo. The tissue-specific delivery is accomplished through modifications of LNP formulations, which involve the binding of certain proteins, enabling recognition by cell receptors in specific organs and facilitating endocytosis. The development of TARGETED DELIVERY TECHNOLOGY has made it possible to precisely target the disease at the site of manifestation, enhancing disease control and reducing the negative effects of systemic protein production.
Our ”sa-RNA CENTER OF EXCELLENCE” has the capacity to manufacture millions of vaccine doses per year for developed and developing nations with a fraction of a typical cost
Our RNA Center of Excellence work together to accelerate the development and delivery of next-generation vaccines and therapeutics through the integration of the following departments/tasks with a minimal cost:
- CMC activities including Process Development and Scale-up of GMP RNA manufacturing
- Innovative Technologies to streamline the sa-RNA manufacturing
- In-house analytical capabilities for sa-RNA analysis, characterization and release testing
- Robust Quality Management Systems
- Regulatory/IND submission
Our Smart-Vaccination Technology Development Program could prevent infectious disease-related morbidity and mortality, especially in low- and middle-income countries (LMICs)
The process for developing new vaccines has changed significantly over the last few years. Luminous mission is to develop saRNA-based vaccines for emerging and re-emerging infectious diseases and to provide low-cost vaccines to low to middle income countries (LMIC) throughout the world. The saRNA platform is flexible and a plug-and-play cassette technology that can be used to produce a range of different target antigens. Our long-term goal is to make our saRNA platform for targeted delivery of antigens available to manufacturers in developing countries.
